COMMUNIQUÉS West-GlobeNewswire

AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
03/01/2019
Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today announced that it has [...]
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
03/01/2019
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys B ioscience, Inc ., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has submitted a pre-IND ( [...]
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554
03/01/2019
Tara Rheault, PhD, MPH, named Vice President, R&D Operations and Global Project Management LONDON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage [...]
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic SteatoHepatitis (NASH)
03/01/2019
GENFIT AND LABCORP SIGN A LICENSING AGREEMENT TO EXPAND ACCESS TO AN INNOVATIVE DIAGNOSTIC ASSAY FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) Multi-Biomarker Test Will Provide the Clinical Research Community with a Non- [...]
GENFIT et LabCorp signent un accord de licence visant l'élargissement de l'accès à un test diagnostique innovant de la stéatohépatite non-alcoolique (NASH)
03/01/2019
GENFIT ET LABCORP SIGNENT UN ACCORD DE LICENCE VISANT L'ÉLARGISSEMENT DE L'ACCÈS À UN TEST DIAGNOSTIQUE INNOVANT DE LA STÉATOHÉPATITE NON-ALCOOLIQUE (NASH) Ce test, basé sur plusieurs biomarqueurs, fournira à la [...]
DBV Technologies Expands and Strengthens Leadership Team
03/01/2019
Montrouge, France, January 3, 2019 DBV Technologies Expands and Strengthens Leadership Team Key medical, manufacturing and regulatory leadership changes announced ahead of anticipated Viaskin Peanut BLA resubmission Dr [...]
DBV Technologies étend et renforce son équipe de management
03/01/2019
Montrouge, France, le 3 janvier (07h30 CET), 2019 DBV Technologies étend et renforce son équipe de management Des changements importants au niveau des directions médicales, des opérations pharmaceutiques, et du [...]
Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
03/01/2019
Accelerates European Development of PSMA-Targeted Imaging Agent with Global Leader in Nuclear Medicine NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company [...]
Kiadis Pharma to present at Biotech Showcase 2019
03/01/2019
Kiadis Pharma to present at Biotech Showcase 2019 Amsterdam, The Netherlands, January 3, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage [...]
aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events
03/01/2019
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Mesa Labs Declares Quarterly Dividend
03/01/2019
Lakewood, Colo., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals
03/01/2019
Company Release no. 01/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 January 2019 Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today [...]
Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study
02/01/2019
First patient enrolled in Phase 3 hip OA registration trial in late December 2018; trial expected to complete in 2020 Positive results from Phase 2 pharmacokinetics (PK) study of ZILRETTA in OA of shoulder and hip [...]
Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San [...]
Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
02/01/2019
WESTLAKE VILLAGE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna [...]
Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
02/01/2019
DURHAM, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 37 th [...]
Radius Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
WALTHAM, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 37 th Annual J.P. [...]
GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, [...]
Otonomy to Present at the J.P. Morgan Healthcare Conference
02/01/2019
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D [...]

Pages